Cabecera 2019 CBMSO CSIC UAM

Wednesday, 21st August 2019

2017.03.01 lev18 mariano barbacid

 

Prof. Mariano Barbacid

 

Centro Nacional de Investigaciones Oncológicas (CNIO)

Galería de Imágenes

 

 

 

 

 

2017 02 17 Mariano Barbacid portminMariano Barbacid es Jefe del Grupo de Oncología Experimental del Centro Nacional de Investigaciones Oncológicas (CNIO). Realizó su Tesis Doctoral en el Centro de Investigaciones Biológicas (CSIC) bajo la dirección del Prof. David Vázquez. Desde 1974 a 1978 realizó una estancia postdoctoral en el National Cancer Institute (NCI) en Bethesda (Maryland, USA). En 1978 comenzó su propio grupo de investigación sobre la biología molecular de tumores humanos. Durante este tiempo realizó dos contribuciones de una gran importancia, el aislamiento en 1982 del primer gen del cáncer en humanos, H-RAS, y la identificación de la primera mutación asociada con el desarrollo del cáncer en humanos. En 1984 se trasladó al NCI-Fredrick en Maryland como Jefe de la Sección “Developmental Oncology” y en 1988 se trasladó al Bristol Myers-Squibb Pharmaceutical Research Institute en Princeton (New Jersey), donde fue Vice-Presidente de “Oncology Drug Discovery”.

En 1998 volvió a Madrid para crear y dirigir el CNIO. En 2011, después de 14 años, dejó la dirección del Centro para concentrarse en su propia investigación, cuyo foco es el diseño de nuevos animales modelo del cáncer y en la identificación y validación de dianas moleculares con valor terapéutico potencial. Su trabajo ha sido reconocido con numerosos premios y distinciones nacionales e internacionales. Entre otros, es miembro de EMBO, de la European Academy of Cancer Sciences, y desde 2012 es miembro extranjero de la US National Academy of Sciences.

 


 

Mariano Barbacid is Leader of the Spanish National Cancer Research Center (CNIO). He worked on the Ph.D. Thesis at the Centro de Investigaciones Biológicas (CSIC), under the direction of Prof. David Vázquez. From 1974 to 1978 he was trained as a postdoctoral fellow at the National Cancer Institute (NCI) in Bethesda (Maryland, USA). In 1978 he started his own group to work on the molecular biology of human tumors. His work led to the isolation in 1982 of the first human cancer gene, H-­‐RAS, and to the identification of the first mutation associated with the development of human cancer. In 1984 he moved to the NCI-­‐Frederick, in Maryland, as Head of the Department of the Developmental Oncology Section, and in 1988 he joined the Bristol Myers-­‐Squibb Pharmaceutical Research Institute in Princeton (New Jersey) where he became Vice-­‐President of Oncology Drug Discovery.

In 1998 he returned to Madrid to create and direct the CNIO. In 2011, after 14 years, he left the direction of the Center to concentrate on his own research that currently focuses on the design of new animal models of cancer and on the identification and validation of molecular targets with potential therapeutic value. His work has been recognized with numerous national and international prizes and distinctions. Among them, he is a Member of EMBO and the European Academy of Cancer Sciences. In 2012 he was elected a Foreign Member of the US National Academy of Sciences.

 

Publicaciones recientes / Recent publications:

  • Ambrogio C, Gómez-López G, Falcone M, Vidal A, Nadal E, Crosetto N, Blasco RB, Fernández­‐Marcos PJ, Sánchez­‐Céspedes M, Ren X, Wang Z, Ding K, Hidalgo M, Serrano M, Villanueva A, Santamaría D, Barbacid M. Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. Nat Med. 2016 Mar;22(3):270-­7. doi:10.1038/nm.4041.
  • Drosten M, Simón-­Carrasco L, Hernández-Porras I, Lechuga CG, Blasco MT, Jacob HK, Fabbiano S, Potenza N, Bustelo XR, Guerra C, Barbacid M. H‐Ras and K­‐Ras Oncoproteins Induce Different Tumor Spectra When Driven by the Same Regulatory Sequences. Cancer Res. 2016 Nov 21. doi: 10.1158/0008-­‐5472.CAN­‐16­‐2925.
  • Ambrogio C, Barbacid M, Santamaría D. In vivo oncogenic conflict triggered by co‐existing KRAS and EGFR activating mutations in lung adenocarcinoma. Oncogene. 2016 Oct 24. doi:10.1038/onc.2016.385.

NOTE! This site uses cookies and similar technologies.

If you not change browser settings, you agree to it. Learn more

I understand

COOKIES POLICY

What are cookies?

A cookie is a file that is downloaded to your computer when you access certain web pages. Cookies allow a web page, among other things, to store and retrieve information about the browsing habits of a user or their equipment and, depending on the information they contain and the way they use their equipment, they can be used to recognize the user.

Types of cookies

Classification of cookies is made according to a series of categories. However, it is necessary to take into account that the same cookie can be included in more than one category.

  1. Cookies according to the entity that manages them

    Depending on the entity that manages the computer or domain from which the cookies are sent and treat the data obtained, we can distinguish:

    • Own cookies: those that are sent to the user's terminal equipment from a computer or domain managed by the editor itself and from which the service requested by the user is provided.
    • Third party cookies: those that are sent to the user's terminal equipment from a computer or domain that is not managed by the publisher, but by another entity that processes the data obtained through the cookies. When cookies are installed from a computer or domain managed by the publisher itself, but the information collected through them is managed by a third party, they cannot be considered as own cookies.

  2. Cookies according to the period of time they remain activated

    Depending on the length of time that they remain activated in the terminal equipment, we can distinguish:

    • Session cookies: type of cookies designed to collect and store data while the user accesses a web page. They are usually used to store information that only is kept to provide the service requested by the user on a single occasion (e.g. a list of products purchased).
    • Persistent cookies: type of cookies in which the data is still stored in the terminal and can be accessed and processed during a period defined by the person responsible for the cookie, which can range from a few minutes to several years.

  3. Cookies according to their purpose

    Depending on the purpose for which the data obtained through cookies are processed, we can distinguish between:

    • Technical cookies: those that allow the user to navigate through a web page, platform or application and the use of different options or services that exist in it, such as controlling traffic and data communication, identifying the session, access to restricted access parts, remember the elements that make up an order, perform the purchase process of an order, make a registration or participation in an event, use security elements during navigation, store content for the broadcast videos or sound or share content through social networks.
    • Personalization cookies: those that allow the user to access the service with some predefined general characteristics based on a series of criteria in the user's terminal, such as the language, the type of browser through which the user accesses the service, the regional configuration from where you access the service, etc.
    • Analytical cookies: those that allow the person responsible for them to monitor and analyse the behaviour of the users of the websites to which they are linked. The information collected through this type of cookies is used in the measurement of the activity of the websites, applications or platforms, and for the elaboration of navigation profiles of the users of said sites, applications and platforms, in order to introduce improvements in the analysis of the data of use made by the users of the service.

Cookies used on our website

The CBMSO website uses Google Analytics. Google Analytics is a simple and easy to use tool that helps website owners to measure how users interact with the content of the site. You can consult more information about the cookies used by Google Analitycs in this link.

Acceptance of the Cookies Policy

The CBMSO assumes that you accept the use of cookies if you continue browsing, considering that it is a conscious and positive action from which the user's consent is inferred. In this regard, you are previously informed that such behaviour will be interpreted that you accept the installation and use of cookies.

Knowing this information, it is possible to carry out the following actions:

How to modify the configuration of cookies

Using your browser you can restrict, block or delete cookies from any web page. In each browser the process is different, here we show you links on this particular of the most used browsers: